Tenosynovial Giant Cell Tumor Excellence Forum

Tenosynovial Giant Cell Tumor

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Interview

Experts Uncover Atypical Gene Fusions in TGCT Via Molecular Profiling

01/20/2020

George Jour, MD, discusses the findings of a study involving the molecular profiling of atypical TGCT.

George Jour, MD, discusses the...

01/20/2020

Oncology

News

DCC-3014 Well-Tolerated, Active in Patients With Diffuse-Type TGCT

12/12/2019

Findings from a phase 1 clinical trial demonstrate that DCC-3014 is active and generally well-tolerated in patients with diffuse-type TGCT.

Findings from a phase 1 clinical...

12/12/2019

Oncology

Podcasts

Evolution of the Treatment Landscape for Tenosynovial Giant Cell Tumors

11/21/2019

Jonathan Trent, MD, PhD, discusses the evolution of the current treatment landscape for TGCT.

Jonathan Trent, MD, PhD,...

11/21/2019

Oncology

Podcasts

Pexidartinib Demonstrates Great Tumor Response in Tenosynovial Giant Cell Tumors

11/13/2019

Brian Van Tine, MD, discusses results from the ENLIVEN trial, which evaluated pexidartinib, a CSF1 receptor inhibitor, in patients with TGCT.

Brian Van Tine, MD, discusses...

11/13/2019

Oncology

News

Imatinib Mesylate Demonstrates Long-Term Efficacy in TGCT

10/20/2019

Results from a retrospective study confirm the long-term efficacy of imatinib mesylate in patients with advanced TGCT.

Results from a retrospective...

10/20/2019

Oncology

Commentary

Surgery Yields High Risk for Recurrence, Complications in Patients With TGCTs

10/08/2019

Surgery is not a definitive treatment for every patient with diffuse-type TGCTs.

Surgery is not a definitive...

10/08/2019

Oncology

Commentary

FDA Approves Pexidartinib for Symptomatic TGCTs

10/08/2019

The FDA has approved pexidartinib to treat certain adults with symptomatic TGCTs.

The FDA has approved...

10/08/2019

Oncology

Pexidartinib Improves Overall Response in Patients with TGCT

09/23/2019

Findings from the ENLIVEN trial suggest pexidartinib as a potential therapy option for tenosynovial giant cell tumor (TGCT) in patients not amenable to surgical resection.

Findings from the ENLIVEN trial...

09/23/2019

Oncology

Section Editor

Robert Maki, MD, PhD

Northwell Health Cancer

Center Institute, New York

Tenosynovial Giant Cell Tumor Excellence Forum

Section Editor

Specialties

Events

Year Round Education

HMP Global Products